Hansa Biopharma (HNSA) investor relations material

Executive summary

• Q1 2026 was a transition period marked by significant organizational restructuring, leadership changes, and system upgrades, with a focus on capital efficiency and U.S. launch preparations.

• Revenue declined to SEK 34.6 million (34.6 MSEK) from 66.3 MSEK year-over-year, mainly due to European restructuring, but demand remained robust in France and improved in Spain and Italy.

• Financial runway was extended through a $30 million convertible note, deferred debt payments, and a major debt payment, with no further payments due until mid-2027.

• Regulatory progress included FDA acceptance of imlifidase BLA, assignment of a PDUFA date for December 19, 2026, and submission of briefing packages for key programs.

• U.S. commercial team expanded, integrating commercial and medical affairs, and new systems and CRM were implemented.

Financial highlights

• Q1 2026 revenue was SEK 34.6 million, a 48% decrease from Q1 2025; product sales were SEK 33.9 million.

• SG&A expenses were SEK 106 million, including a one-off 10 MSEK cost related to convertible note financing, and increased due to U.S. launch investments.

• R&D expenses were SEK 57 million, down from Q1 2025, reflecting clinical trial wind-down and restructuring.

• Loss from operations was SEK 143 million, compared to SEK 93 million in Q1 2025.

• Cash and cash equivalents at quarter-end totaled SEK 677 million.

Outlook and guidance

• No detailed guidance for 2026, but growth is expected in the second half, driven by new data releases, regulatory milestones, and organizational changes.

• Early Q2 shows improved sales trends in Europe; key milestones include PAES data, ConfIdeS Phase 3 data at ATC in June, and EMA full approval filing in Q4.

• U.S. launch preparations are on track, focusing on access, reimbursement, and transplant center readiness ahead of the December PDUFA date.